Based on the results from the registrational phase 1/2 ARROW study (NCT03037385)10,11, pralsetinib was approved in several countries globally, including the United States, for treatment of metastatic RET fusion–positive NSCLC, advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancer12, as well as in the European Union for treatment of advanced RET fusion–positive NSCLC13. Here, RET is linked to non-small cell lung carcinoma.